Objective: Recommendations for the diagnosis of preclinical Alzheimer disease (AD) have
been formulated by a workgroup of the National Institute on Aging and Alzheimer's …

Objective: A workgroup commissioned by the Alzheimer's Association (AA) and the National
Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease …

Abstract The National Institute of Aging and Alzheimer's Association (NIA-AA) criteria for
Alzheimer disease (AD) treat neuroimaging and cerebrospinal fluid (CSF) markers of AD …

Background To operationalize the National Institute on Aging–Alzheimer's Association (NIA‐
AA) Research Framework for Alzheimer's Disease 6‐stage continuum of clinical progression …

Objective: To determine whether clinically nondemented elderly individuals with
pathologically confirmed preclinical AD are characterized by cognitive decline as measured …

Objective To determine the prevalence of preclinical Alzheimer disease (AD) according to
current classification systems by examining CSF from a representative general population …

Objective The newly proposed National Institute on Aging–Alzheimer's Association (NIA‐AA)
criteria for mild cognitive impairment (MCI) due to Alzheimer disease (AD) suggest a …

To test the validity of the new diagnostic criteria for Alzheimer's disease (AD) in a naturalistic
series of patients with mild cognitive impairment (MCI). Ninety consecutive MCI patients …

Objectives: We compared the ability of molecular biomarkers for Alzheimer disease (AD),
including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181, tau/Aβ42 …

Objective To determine the time required for a preclinical Alzheimer disease population to
decline in a meaningful way, use estimates of decline to update previous clinical trial design …